New hope for stomach cancer patients: experimental drug targets HER2-positive tumors

NCT ID NCT07152405

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times

Summary

This study tests a new drug called BL-M07D1 in people with advanced stomach or gastro-esophageal junction cancer that is HER2-positive and has stopped responding to first-line anti-HER2 therapy. About 490 adults will be randomly assigned to receive either BL-M07D1 or standard chemotherapy. The goal is to see if the new drug helps people live longer or slows cancer growth better than current options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, China

Contact
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, China

Contact

Conditions

Explore the condition pages connected to this study.

GASTRIC ADENOCARCINOMA GASTRIC OR GASTRO ESOPHAGEAL JUNCTION ADENOCARCINOMA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA